This paper is in the following e-collection/theme issue:

Methods and Feasibility Studies (380) Cancer and Clinical Trials (19)

Published on in Vol 6, No 3 (2017): March

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility

Authors of this article:

Bin Li1 Author Orcid Image ;   Steven A Eschrich2 Author Orcid Image ;   Anders Berglund2 Author Orcid Image ;   Melissa Mitchell3 Author Orcid Image ;   David Fenstermacher4 Author Orcid Image ;   Hadi Danaee5 Author Orcid Image ;   Hongyue Dai6 Author Orcid Image ;   Daniel Sullivan7 Author Orcid Image ;   William L Trepicchio5 Author Orcid Image ;   William S Dalton3 Author Orcid Image
Article Authors Cited by (6) Tweetations (2) Metrics

Journals

  1. Sharman J, Wheler J, Einhorn L, Dowlati A, Shapiro G, Hilton J, Burke J, Siddiqi T, Whiting N, Jalal S. A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. Investigational New Drugs 2019;37(4):738 View
  2. Xu M, Gabali A, Hsi E, Fedoriw Y, Vij K, Salama M, Ramchandren R, O’Malley D, Wick M, Battistella M, Gru A. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. American Journal of Surgical Pathology 2020;44(2):e1 View
  3. Stillman R. Clinical Decision Support Tools Improving Cancer Care. Seminars in Oncology Nursing 2018;34(2):158 View
  4. Dalton W, Sullivan D, Ecsedy J, Caligiuri M. Patient Enrichment for Precision‐Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. Clinical Pharmacology & Therapeutics 2018;104(1):23 View
  5. Nassif S, El-Zaatari Z, Attieh M, Hijazi M, Fakhreddin N, Aridi T, Boulos F. Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics. Medicine 2019;98(32):e16702 View

Books/Policy Documents

  1. Lin T, Eroglu Z, Carvajal R, Markowitz J. Translational Bioinformatics for Therapeutic Development. View